UPM-Kymmene: Why It's Now Over 2.5% Of My Portfolio

An analyst reiterates a "Buy" rating for UPM-Kymmene (UPMKF), a global paper and forest company, with a price target of €35/share, citing a potential total rate of return of over 100% in 3-5 years despite expecting flat earnings for 2025 due to geopolitical instability and FX headwinds; the analyst highlights UPM's strong balance sheet, low leverage, and ongoing share repurchases as indicators of financial health, and notes the company's undervaluation compared to peers, while acknowledging cyclical market risks.

Analysis

UPM-Kymmene (UPMKF, UPMMY) is presented as an undervalued global paper and forest products company with significant long-term upside potential, despite an anticipated flat earnings performance in 2025. The company demonstrated robust 2024 results, with EBIT rising over 20% and sales increasing by 4%, partly driven by contributions from new assets like UPM Paso de los Toros. However, 1Q25 saw a slight sales growth but an EBIT decline of approximately 14% due to challenging comparisons and macroeconomic headwinds, with most segments, except Fibres, experiencing year-over-year declines. UPM is emerging from a heavy capital expenditure cycle, which increased fixed costs by over €100 million in 2024, and is now focused on operational efficiency. Financially, UPM maintains a strong BBB+ credit rating and low leverage (net debt/EBITDA below 1.8x at 1Q25 end), even after significant investments. This financial health is further evidenced by a €1.5/share dividend (yielding over 6% at current sub-€25/share prices) and an active share repurchase program, with €116 million in shares bought back in 1Q25. The company holds leading market positions in segments such as multi-fibres, Raflatac, specialty papers, and European plywood, with developing potential in energy and biochemicals. While 2025 earnings are forecast to be slightly lower than 2024, with an estimated EPS of €1.67, a substantial recovery is projected by 2027E with EPS reaching €2.67. This projected growth, combined with a current NTM P/E of 13.6x (considerably lower than peers like SCA at 23x and Holmen at 21x), underpins the analyst's price target of €35/share and a potential total return exceeding 100% within 3-5 years. Key risks include the cyclicality of its end markets, volatility in its energy segment, and the nascent stage of its bio-initiatives, though exposure to U.S. tariffs is considered limited. FX fluctuations are a noted consideration.

Key Decisions for Investors

• Consider UPM-Kymmene for long-term investment portfolios, aligning with the analyst's projected 3-5 year horizon for significant returns as the company transitions out of its CapEx-heavy cycle and markets potentially normalize.
• Evaluate the current valuation, with a NTM P/E of 13.6x and a dividend yield over 6%, as a potentially attractive entry point, reinforced by ongoing share repurchases which signal management's confidence in the company's prospects.
• Monitor key catalysts such as the normalization of end-market demand for paper and pulp, the operational ramp-up of new assets, progress in the bio-segments, and foreign exchange movements, as these will be crucial for achieving the forecasted EPS growth towards €2.67 by 2027E.
• Acknowledge the expected earnings trough in 2025 and the inherent cyclicality of the industry, suggesting patience and a focus on the company's strong balance sheet and market leadership during periods of market uncertainty.